期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

包载甲氨蝶呤的聚乙交酯丙交酯纳米颗粒的制备与体外释药机制研究 被引量：2

Preparation and Mechanism Study on Release in vitro of Methotrexate Loaded Poly(Lactic-co-glycolic) Nanoparticles
下载PDF
导出
摘要 目的制备包载甲氨蝶呤(MTX)的聚乙交酯丙交酯(PLGA)纳米颗粒并研究体外释药机制。方法采用溶剂挥发法制备包载MTX的PLGA纳米颗粒,对其形貌、大小进行表征,测定体外释药曲线,并采用药学模型进行拟合。结果纳米颗粒平均粒径为175.9nm,具有明显的缓释作用,释药行为最符合双相动力学方程。结论该研究为开发MTX的新剂型提供了实验依据。 Objective To prepare methotrexate（MTX） loaded poly（lactic-co-glycolic）（PLGA） nanoparticles and investigate the mechanism on release in vitro.Methods MTX-loaded nanoparticles were prepared by emulsion solvent evaporation method.The morphology and size of nanoparticles were studied,and in vitro release curve was measured.Moreover,the release data were fitted with different mathematical models.Results The mean size of nanoparticleas was 175.9nm,and the obtained nanoparticles showed evidently sustained release effect. The release behavior of MTX loaded nanoparticles was well fitted to the double phase dynamic equation. Conclusion The work provides an experiment basis for the development of novel ideal administration of MTX.
作者 郑明彬 龚萍 杨雪梅 吴喜仁 梅俊
机构地区 广东医学院化学教研室 中国科学院深圳先进技术研究院生物医学与健康工程研究所
出处 《时珍国医国药》 CAS CSCD 北大核心 2009年第11期2812-2813,共2页 Lishizhen Medicine and Materia Medica Research
基金 广东省科技计划项目(No.2007B01060038) 广东省科技计划项目(No.2006B14701008) 广东医学院青年基金(No.XQ0718)
关键词 甲氨蝶呤 聚乙交酯丙交酯 纳米颗粒 拟合 Methotrexate Poly（lactic-co-glycolic） Nanoparticles Fit
分类号 R283 [医药卫生—中药学]
  • 相关文献

参考文献4

二级参考文献21

  • 1[1]Mauger JW,Chilko D,Howard S.On the analysis of the dissolution data[J].Drug Dev Ind Pharm,1986,12 (7):969-992.
  • 2[2]Polli JE,Rekhi GS,Augsburger LL,et al.Methods to compare dissolution profiles and a rationale for wide dissolution specifications for metoprolol tartrate tablets[J].JPharm Sci,1997,86 (6):690-700.
  • 3[3]Sathe PM,Tsong Y,Shah VP.In-vitro dissolution profile comparison:statistics and analysis,model dependent approach[J].Pharm Res,1996,13 (12):1799-1803.
  • 4[4]Moore JW,Flanner HH.Mathematical comparison of dissolution profiles [J].Pharm Technol,1996,20 (6):64-74.
  • 5[5]Podczeck F.Comparison of in vitro dissolution profiles by calculating mean dissolution time (MDT) or mean residence time (MRT) [J].Int J Pharm,1993,97 (1-3):93-100.
  • 6[6]Shah VP,Tsong Y,Sathe P,et al.In vitro dissolution profile comparison--statistics and analysis of the similarity factor,f2 [J].Pharm Res,1998,15 (6):889-896.
  • 7Ashington C. Drug release from microdisperse systems: a critical review [J].Int J Pharm, 1990,58(1) :1 - 12.
  • 8Levy MY, Benita S. Drug release from submicronized O/W emulsion: a new in vitro kinetic evaluation model[J]. Int J Pharm, 1990, 66(1 - 3) :29 - 37.
  • 9Shah N H, Carvajal M T, Patel C I. Self - emulsifying drug delivery systems (SEDDS) with polyglycolyzed glycerides for improving in vitro dissolution and oral absorption of lipophilic drugs [J]. Int J Pharm, 1994, 106(1):15-23.
  • 10Reddy KR.Controlled-release,pegylation,liposomal formulations:new mechanisms in the delivery of injectable drugs[J].Ann Pharmacother,2000,34:915-918.

共引文献30

同被引文献31

  • 1章怡彬,梁文权,高建青.纳米粒作为抗肿瘤药物载体的研究进展[J].医药导报,2006,25(6):551-553. 被引量：6
  • 2王璐璐,朱林,倪坤仪,屠颖,肖莹,彭国罡.HPLC研究甲氨喋呤磁靶向脂质体在小鼠体内的组织分布[J].中国药学杂志,2006,41(20):1572-1575. 被引量：10
  • 3OWEN H,GRAHAM S,WERLING J O,et al.Anion effects on electrostatic charging of sterically stabilized,water insoluble drug particles[J].Int J Pharm,2009,368(1-2):154-159.
  • 4TWYMAN L J,BEEZER A E,ESFAND R,et al.The synthesis of water soluble dendrimers,and their application as possible drug delivery systems[J].Tetrahedron Lett,1999,40(9):1743-1746.
  • 5KOLHE P,MISRA E,KANNAN R M,et al.Drug comple-xation,in vitro release and cellular entry of dendrimers and hyperbranched polymers[J].Int J Pharm,2003,259(1-2):143-160.
  • 6KOJIMA C,KONO K,MARUYAMA K,et al.Synthesis of polyamidoamine dendrimers having poly(ethylene glycol) grafts and their ability to encapsulate anticancer drugs[J].Bioconjug Chem,2000,11(6):910-917.
  • 7Danhier F, Ansorena E, Silva J M, et al. PLGA - based nanoparticles : an overview of biomedical applications [ J ]. J Control Release,2012 , 161 (2) :505 - 522.
  • 8Dong Y, Feng S S. Methoxy poly ( ethylene g/ycol) - poly (lactide) ( MPEG - PLA) nanoparticles for controlled de- livery of antieancer drugs [ J ]. Biomaterials, 2004, 25 (14) :2843 -2849.
  • 9Feng S S, Mu L, Win K Y, et al. Nanoparticles of biode- gradable polymers for clinical administration of paclitaxel [ J]. Curr Med Chem,2004,11 (4) :413 -424.
  • 10Gunny R, Peppas N A, Harrington D D, eta/. Development of biodegradable and injectable latices for controlled re- lease of potent drugs [ J ]. Drug Dev Ind Pharm, 1981 (7) : 1 - 25.

引证文献2

二级引证文献1

时珍国医国药
2009年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部